WATERTOWN, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointment of Antonio Gualberto, MD, PhD, as President of Research & Development and Chief Medical Officer.
“It is my pleasure to welcome Antonio to Exo and work with him as we continue to progress our programs,” said Michael Bruce, PhD, CEO of Exo Therapeutics. “Antonio is an outstanding leader with broad experience gained at both small and large biopharmaceutical companies. He will be an invaluable addition to our team as we advance our pipeline toward the clinic in service to patients suffering from serious diseases.”
“The reprogramming of proteins via exosites is a unique drug development approach with great potential and compelling early data. I’m excited to lead the discovery and development of these novel agents,” said Dr. Gualberto. “I look forward to working with the extraordinary team at Exo on expanding a pipeline of drugs addressing multiple indications with a high unmet medical need.”
“I have had the pleasure of working with Antonio previously and have seen his impactful contributions firsthand,” said Thilo Schroeder, PhD, Board of Directors member of Exo Therapeutics. “As Exo continues to rapidly strengthen its ExoSightTM platform, it is a perfect time to add someone with Antonio’s superb R&D expertise and ability to advance our programs.”
Dr. Gualberto brings over 20 years of drug development experience, spanning candidate selection to registration and market access. Before joining Exo, Dr. Gualberto served as CMO at H3 Biomedicine, a subsidiary of Eisai Ltd., where he led the development of the ERα inhibitor H3B-6545 and the SF3B1 modulator H3B-8800, among others. Prior to H3B, he was CMO and co-founder at Kura Oncology where he led the clinical proof-of-concept of farnesyl transferase inhibitors. Prior to Kura, he held positions of increasing responsibility at EMD Serono, Takeda and Pfizer where he contributed to the development of erlotinib, tremelimumab, neratinib and brentuximab vedotin. Dr. Gualberto received his MD and PhD degrees from the University of Seville in Spain, trained at the University of North Carolina at Chapel Hill and the Berkeley National Laboratory, and held academic faculty positions at Case Western Reserve University and Brown University.
About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit www.exo-therapeutics.com.
